

## HR 6033

### Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act

**Congress:** 114 (2015–2017, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Sep 14, 2016

**Current Status:** Referred to the House Committee on Energy and Commerce.

**Latest Action:** Referred to the House Committee on Energy and Commerce. (Sep 14, 2016)

**Official Text:** <https://www.congress.gov/bill/114th-congress/house-bill/6033>

## Sponsor

**Name:** Rep. Peters, Scott H. [D-CA-52]

**Party:** Democratic • **State:** CA • **Chamber:** House

## Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Boyle, Brendan F. [D-PA-13]	D · PA		Sep 14, 2016
Rep. Rothfus, Keith J. [R-PA-12]	R · PA		Sep 14, 2016

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Sep 14, 2016

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

No related bills are listed.

## Summary (as of Sep 14, 2016)

### Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act

This bill amends the Federal Food, Drug, and Cosmetic Act to add Middle East respiratory syndrome to the list of tropical diseases under the priority review voucher program, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.)

## Actions Timeline

- **Sep 14, 2016:** Introduced in House
- **Sep 14, 2016:** Referred to the House Committee on Energy and Commerce